STAT December 17, 2019
The days of the blockbuster drug might not be over, but they are dwindling. As markets become more crowded, pharmaceutical companies are focusing their drug development strategies on specialized populations, such as individuals with rare diseases or those with genetic subsets of chronic conditions like cancer and diabetes and cardiovascular diseases.
Identifying a specific subgroup of patients from a niche population poses challenges for many companies.
The integration of artificial intelligence (AI) and machine learning (ML) in a drug development and launch playbook offers new possibilities to find the right subpopulation(s) for product targeting as a way to ensure a successful launch.
With the growth of big data and exponential advancements in technology, we are seeing more opportunities to apply...
Today's Sponsors
Today's Sponsor